https://www.nxtpsychedelics.com/news/articles/law-regulation/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of/